A Phase 4 interventional study of Apieron Insight eNO monitor in Asthma, sponsored by Apieron. Terminated at 12 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2009-01-21.
Sponsored by Apieron · Phase 4, Interventional, and Treatment
This study is designed to show that pharmacotherapy guided by eNO and clinical standard of care produces a superior outcome to trial-based therapy guided by clinical standard of care alone.
Patients with persistent, moderate to severe asthma will be randomized to receive therapy guided by either eNO and clinical standard of care (eNO group) or clinical standard of care (control group). An eNO treatment algorithm will be established for each patient in the eNO group at Baseline (Visit 1). Enrollment is estimated to be six months with a follow up period of twelve months.
3,921 studies on the registry are indexed under Asthma; 507 are open to participants now.
This study's enrollment of 260 is above the median of 83 across 2,752 interventional studies indexed under Asthma.
Browse Asthma studies →Apieron is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
eNO measurement is used to inform asthma management decisions
Device: Apieron Insight eNO monitor
Asthma is managed according to existing standard of care
The Apieron Insight(tm) eNO monitor is used to measure exhaled nitric oxide, and asthma is managed to keep eNO below an individualized target.
Asthma control days
Time frame: 12 months
This study is terminated, as verified in Oct 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Apieron